Faeth to use funds to advance AI-based nutrition platform for cancer treatment

Faeth Therapeutics, which is developing machine learning-based precision nutrition solutions and treatment regimens to enhance cancer therapy, announced on Tuesday that it raised $20 million in seed financing.

CEO Anand Parikh remarked "we're excited…to solve the existing challenge of how nutrition can be harnessed to improve outcomes across oncology using our machine learning-driven precision nutrition platform, MetabOS." He added that "this seed financing round enables us to begin first-in-human studies for our lead candidate serabelisb and advance our precision therapeutics pipeline augmented by precision nutrition."

Exploiting unique metabolism, nutrient uptake of cancer cells

Specifically, the funds will be used to advance MetabOS as well as the isoform-selective PI3Kα inhibitor serabelisb into Phase Ib/II trials this year. The company said it will also be expanding its team to further develop its MetabOS preclinical discovery platform and patient-facing software.

Faeth explained that it aims to exploit the differences in metabolism and nutrient uptake between healthy and cancerous tissues with precision nutrition, which could also improve patient responses to cancer therapies. The company is using MetabOS to uncover the precise nutrient vulnerabilities for a tumour based on genotype, organ of origin and therapy.

To ensure you don't miss other Top Stories like these and news on key healthtech industry developments, sign up for our free daily e-newsletter here.